<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840875</url>
  </required_header>
  <id_info>
    <org_study_id>BRYY-IIT-LCYJ-2021-004</org_study_id>
    <nct_id>NCT04840875</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma</brief_title>
  <official_title>Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Boren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Boren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial of autologous CD7-CAR T cells in the treatment of high-risk&#xD;
      acute T-cell leukemia / lymphoma. Twenty subjects will be enrolled. Subjects will be&#xD;
      pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells&#xD;
      transfusion, the patients who planned to reinfuse CAR T cells were treated with&#xD;
      fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface&#xD;
      area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1&#xD;
      (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at&#xD;
      the PI's discretion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>Time Frame: 1 month</time_frame>
    <description>The complete remission(CR) rate to the CAR-T treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>T Cell Lymphoma</condition>
  <condition>T-cell Leukemia</condition>
  <arm_group>
    <arm_group_label>chimeric antigen receptor T cell treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>chimeric antigen receptor T cell treatment</intervention_name>
    <description>Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.</description>
    <arm_group_label>chimeric antigen receptor T cell treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Diagnosed as a high-risk acute T-cell leukemia / lymphoma patient with complete&#xD;
             remission within 3 months and persistent positive of minimal residual disease,&#xD;
             expressing tumor surface antigen CD7&#xD;
&#xD;
          2. Male or female, aged 0-70 years&#xD;
&#xD;
          3. No serious allergic constitution&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score&#xD;
             0 to 2&#xD;
&#xD;
          5. Have life expectancy of at least 60 days based on investigator's judgement&#xD;
&#xD;
          6. CD7 positive in bone marrow or peripheral blood or immunohistochemistry&#xD;
&#xD;
          7. Candidates aged 8-70 years need to be sufficiently conscious and able to sign the&#xD;
             treatment consent form and voluntary consent form. And Pediatric patients under 8&#xD;
             years old could be recruited after signing an informed consent form by a legal&#xD;
             surrogate (Guardian)&#xD;
&#xD;
          8. Minimal residual disease was positive after chemotherapy and there were&#xD;
             contraindications of allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Intracranial hypertension or disorder of consciousness&#xD;
&#xD;
          2. Symptomatic heart failure or severe arrhythmia&#xD;
&#xD;
          3. Symptoms of severe respiratory failure&#xD;
&#xD;
          4. Complicated with other types of malignant tumors&#xD;
&#xD;
          5. Diffuse intravascular coagulation&#xD;
&#xD;
          6. Serum creatinine and / or blood urea nitrogen ≥ 1.5 times of the normal value&#xD;
&#xD;
          7. Suffering from septicemia or other uncontrollable infections&#xD;
&#xD;
          8. Patients with uncontrollable diabetes&#xD;
&#xD;
          9. Severe mental disorders&#xD;
&#xD;
         10. Obvious and active intracranial lesions were detected by cranial magnetic resonance&#xD;
             imaging (MRI)&#xD;
&#xD;
         11. Have received organ transplantation (excluding hematopoietic stem cell&#xD;
             transplantation);&#xD;
&#xD;
         12. Reproductive-aged female patients with positive blood HCG test&#xD;
&#xD;
         13. Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS&#xD;
             or syphilis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Pan</last_name>
    <phone>+8618911067969</phone>
    <email>panj@borenhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Boren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Pan, Master</last_name>
      <phone>+8618911067969</phone>
      <email>panj@borenhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

